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Abstract
BACKGROUND
Studies have demonstrated a potential role for fecal biomarkers such as fecal
calprotectin (FC) and fecal lactoferrin (FL) in monitoring inflammatory bowel
diseases (IBD) - Crohn’s disease (CD) and ulcerative colitis (UC). However, their
correlation to endoscopic scores, disease severity and affected intestinal surface
has not been extensively investigated.
AIM
To correlate FL, and for comparison white blood cell (WBC) and C-reactive
protein (CRP), with endoscopic scores, disease extent and location in CD and UC.
METHODS
Retrospective analysis in 188 patients who had FL, CRP and WBC determined
within 30 d of endoscopy. Disease location, disease extent (number of intestinal
segments involved), disease severity (determined by endoscopic scores), timing
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of FL testing in relation to colonoscopy, as well as the use of effective fast acting
medications (steroids and biologics) between colonoscopy and FL measurement,
were recorded.
RESULTS
In 131 CD and 57 UC patients, both CRP and FL - but not WBC - distinguished
disease severity (inactive, mild, moderate, severe). In patients receiving fast-
acting (steroids or biologics) treatment in between FL and colonoscopy, FL
showed a higher correlation to endoscopic scores when tested before vs after the
procedure (r = 0.596, P < 0.001, vs r = 0.285, P = 0.15 for the Simple Endoscopic
Score for CD; and r = 0.402, P = 0.01 vs r = 0.054 P = 0.84 for Disease Activity
Index). Finally, FL was significantly correlated with the diseased mucosal surface
(colon-ileocolon > small bowel) and the number of inflamed colon segments.
CONCLUSION
FL and CRP separated disease severity categories with FL showing lower
discriminating P-values. FL showed a close correlation with the involved
mucosal surface and with disease extent and was more closely correlated to
endoscopy when determined before the procedure – this indicating that
inflammatory activity changes associated with therapy might be rapidly reflected
by FL levels. FL can accurately and timely characterize intestinal inflammation in
IBD.
Key words: Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Fecal
lactoferrin; C-reactive protein; White blood cell count; Mucosal inflammation
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Studies have demonstrated a potential role for fecal biomarkers such as fecal
calprotectin and fecal lactoferrin (FL) in monitoring Crohn’s disease (CD) and ulcerative
colitis (UC). However, their correlation with disease burden (endoscopic scores/disease
activity and disease extent) has not been extensively investigated. In our study FL
separated disease severity categories based on endoscopic scores in both UC and CD
patients. FL showed a close correlation with the diseased mucosal surface and with
disease extent and was more closely correlated to endoscopy when determined before
endoscopy. FL can accurately and timely represent intestinal inflammation in
inflammatory bowel diseases.
Citation: Rubio MG, Amo-Mensah K, Gray JM, Nguyen VQ, Nakat S, Grider D, Love K,
Boone JH, Sorrentino D. Fecal lactoferrin accurately reflects mucosal inflammation in




Inflammatory bowel disease (IBD), both Crohn’s disease (CD) and ulcerative colitis
(UC), are on the rise worldwide, including Asia[1-3]. In the United States, 3.1 million
people are reported to be affected[4]. The annual burden of IBD is extensive, with over
2.3 million physician visits, 180000 hospital admissions, and a cost of $6.3 billion in
healthcare services[5-7]. One third of the annual cost of healthcare for IBD patients is
classified as outpatient services, with the major components being endoscopy and
pathology[7].
IBD activity has traditionally been monitored by the severity of clinical symptoms,
using clinical scoring systems such as the Crohn’s Disease Activity Index (CDAI) for
CD and the clinical component of the Mayo score for UC[8]. However, these measures
are subjective and correlate poorly with objective findings[9].
Endoscopy  is  a  more  objective  parameter  of  disease  activity  than  clinical
symptoms[10,11], but it is expensive, invasive, and often unwelcomed by patients. A
number of studies have shown that fecal biomarkers, specifically fecal lactoferrin (FL)
and fecal calprotectin (FC),  are effective indicators of mucosal inflammation and
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injury[8,13-16]. Fecal biomarkers have been shown to be inexpensive, noninvasive, and
reproducible, and they have a strong potential for use in monitoring IBD[12]. Both FC
and FL have shown similar success clinically, and levels may rise significantly before
clinical  relapse  and may predict  subsequent  IBD flares[17].  FL is  an  iron-binding
glycoprotein expressed by active neutrophils-the primary component of the active
inflammatory response[18,19]. FL is stable at room temperature for weeks, resistant to
proteolysis, and resilient to multiple freeze-thaw cycles[20,21].
In a recent meta-analysis evaluating the diagnostic accuracy of FL in assessing IBD
activity Dai and colleagues[22] found that in ten studies comprising 773 IBD patients
the pooled sensitivity and specificity values for assessing UC activity were 0.81 [95%
confidence interval  (CI):  0.64-0.92]  and 0.82 (95%CI:  0.61-0.93),  respectively.  The
pooled sensitivity and specificity values for assessing CD activity were 0.82 (95%CI:
0.73-0.88) and 0.71 (95%CI: 0.63-0.78), respectively.
FL appears to be equally useful in CD and UC, when active or inactive disease is
present[23].  The  current  knowledge  gap  lies  in  an  incomplete  understanding  of
correlation between FL levels and mucosal inflammation, disease location and extent.
In  this  retrospective  study  we  investigated  the  correlation  between  these
parameters and FL levels and compared them to C-reactive protein (CRP) and white
blood cell count (WBC), two widely used indicators of inflammation.
MATERIALS AND METHODS
Study population
This  retrospective study enrolled patients  seen in our Center  from 2008 to  2018,
diagnosed  with  UC  or  CD  according  to  widely  established  criteria  including
histology[24] and were monitored as standard of care through the measurement of FL
levels. To be enrolled in the study patients had to have a colonoscopy done within 30
d of the FL test.
All clinical and laboratory data were collected from the patients’ EMR (EPIC) and
endoscopy data from images and reports stored in the Olympus Endoscopy Suite
Program (Endoworks  7.4).  There  was  no  direct  patient  involvement.  The  study
protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by Carilion Clinic Ethical Committee. No patient consent
was deemed necessary by the Ethical Committee.
Biomarker testing
FL stool  test  (normal  range  0-7.24  μg/mL)  was  measured  quantitatively  by  the
LACTOFERRIN SCAN (TECHLAB,  Blacksburg,  VA,  United States),  an  enzyme-
linked immunosorbent assay (ELISA). Serum measurements of CRP and WBC used
established clinical laboratory methods.
Assessment of disease activity
For each IBD patient in this study, we reviewed endoscopic pictures and procedure
reports  to  determine  the  severity  of  inflammation,  mucosal  injury,  and  disease
location (see “Endoscopic scoring and disease extent” below). In CD patients, disease
location  was  also  based  on  magnetic  resonance  imaging  (MRI)  or  computed
tomography (CT) scan image results. The imaging reviewer was blinded to these
patients FL levels at the time of the evaluation.
Endoscopic scoring and disease extent
The Simple Endoscopic Score for CD (SES-CD) (Supplementary Table 1)  and the
endoscopic component of the Mayo Clinical score [Disease Activity Index (DAI)]
(Supplementary  Table  2)  for  UC  were  utilized  to  measure  endoscopic  disease
activity[9]. The SES-CD defines: Remission (score 0-2), mild inflammation (score 3-6),
moderate  inflammation  (score  7-15),  and  severe  inflammation  (score  ≥  16).  The
endoscopic  component  of  the  DAI defines:  Normal  or  inactive  disease  (0),  mild
disease (1),  moderate disease (2),  and severe disease (3).  Since the DAI does not
include a measure of disease extent,  we estimated this parameter using a simple
scoring  system providing  one  point  for  each  colonic  segment  (rectum,  sigmoid,
descending, transverse, ascending, cecum, ileo-cecal valve) demonstrating signs of
disease. A score of 0 points indicates no disease and a score of 7 points indicates pan-
colitis.
Statistical analysis
Descriptive statistics were used for patients’  characteristics.  Analysis of variance
(ANOVA) was used on natural  log-transformed values  of  FL,  CRP and WBC to
determine whether median values significantly varied according to SES-CD and DAI
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scores. The values were natural log transformed for use in the analysis to address the
non-normality of the distributions of the biomarkers, resulting in a comparison of
median values on the original scale. Post-hoc pairwise comparisons using the method
of least significant differences were used to determine which levels of SES-CD and
DAI  significantly  differed  in  median  biomarker  values  from other  levels.  Non-
parametric Spearman correlations (due to non-normality of variables) were used to
quantify  and  test  the  correlation  of  numeric  SES-CD  and  DAI  with  FL  levels,
separately for patients whose FL levels were determined pre- and post-colonoscopy.
To contrast FL levels with the number of colonic segments involved the Kruskal
Wallis test followed by pairwise Mann-Whitney comparisons was used. The 0.05 level
of significance was used for all statistical tests. The statistical review of the study was
performed by a biostatistician (Love K).
RESULTS
Patient population
Using the inclusion criteria outlined in methods and data search spanning from 2008
to 2018 we identified a  total  of  188 IBD patients  followed at  Carilion Clinic  IBD
Center. The colonoscopy procedures were performed for standard of care indications
(surveillance, monitoring or disease staging). Patient characteristics and clinical data
are shown in Table 1. Overall, 59% of patients were female and 70% had CD. DAI
scoring in UC patients showed mild disease in 19%, moderate disease in 48% and
severe disease in 33%. Of the CD patients scored by SES-CD using the endoscopy
results 10% had inactive disease, 22% had mild disease, 28% had moderate disease
and  40%  had  severe  CD.  A  total  of  63%  of  UC  patients  had  disease  extending
proximal to the splenic flexure (with 2/3 of patients having pancolitis),  30% had
disease distal to the splenic flexure and 7% had proctitis. Of the CD patients 34% had
ileal disease, 22% had ileocolonic disease and 44% had colonic involvement. In the CD
group, 18% of CD patients had stricturing disease with 73% bearing non-stricturing,
non-penetrating disease.
Biomarker levels according to disease severity
The biomarkers FL, CRP and WBC were evaluated as potential indicators of IBD
disease severity as determined by endoscopic scores. In CD patients, FL median levels
showed a significant difference for inactive (20 µg/g) vs mild (102 µg/g), inactive vs
moderate (104 µg/g), mild vs severe (762 µg/g) and moderate vs severe activity. CRP
median levels were significantly different for inactive (0.41 mg/dL) vs severe (2.43
mg/dL),  and mild (0.87 mg/dL) vs  severe activity (Figure 1).  In UC patients,  FL
separated mild (56 µg/g) vs moderate (427 µg/g), and mild vs severe (766 µg/g) cases.
CRP was significantly different between mild (0.35 mg/dL) vs severe (1.60 mg/dL),
and moderate (0.55 mg/dL) vs  severe cases (Figure 2).  WBC median levels were
similar  across  all  categories  for  both  CD and  UC.  Comparisons  contrasting  the
accuracy in discriminating different disease activities showed less significant P values
for CRP than for FL.
Correlation of biomarkers with endoscopic scores
Biomarker concentrations were compared to individual endoscopic scores for CD and
UC patients. Overall, both FL and CRP showed the highest Spearman correlations to
SES-CD and DAI scores for all assessed patients (Table 2). WBC had a very weak
correlation to both the SES-CD and DAI scores. Next, we selected patients (n = 139) in
whom fast  acting  therapy  (steroids  and  biologics)  was  successfully  initiated  in
between FL and colonoscopy. When patients were stratified in two groups according
to the timing of FL testing (Table 3) FL showed a higher correlation to SES-CD and
DAI when it had been tested before the procedure compared to when it had been
tested after the procedure: for SES-CD r = 0.596, P < 0.001, vs r = 0.285, P = 0.149 (n =
58 and 27, respectively); for DAI r = 0.402, P = 0.012, vs r = 0.054, P = 0.842 (n = 38 and
16, respectively).
Biomarker levels according to disease location and extent of colonic disease
Of the 188 IBD patients included in the study, a total of 114 patients had colonic
disease, 45 had isolated small bowel disease and 29 patients had both colonic and
small  bowel  disease.  FL,  CRP and WBC levels  relative  to  disease  location  were
determined in 188, 152 and 153 patients, respectively. FL levels were significantly
higher  in  patients  with  colonic  and  combined  colonic  and  small  bowel  disease
compared to patients with small bowel disease only (Figure 3A) with 69% of the latter
patients having elevated (> 7.25 µg/g) levels of FL. CRP showed a similar trend with
elevated levels being present in 44% of patients with small bowel disease (Figure 3B).
WJGP https://www.wjgnet.com December 31, 2019 Volume 10 Issue 5
Rubio MG et al. Fecal lactoferrin reflects mucosal inflammation
57
Table 1  Patient characteristics, n (%)
Characteristics UC (n = 57) CD (n = 131)
Gender Female 27 (47) 83 (63)
Male 30 (53) 48 (37)
Disease duration (yr) 0-5 37 (65) 72 (55)
6 to 10 9 (16) 16 (12)
> 10 11 (19) 43 (33)
Smoking Current 1 (2) 32 (25)
Former 29 (51) 37 (28)
Never 27 (47) 62 (47)
Biomarkers Lactoferrin μg/g 448 (0; 8467) 95 (0; 9351)
Median (min; max) CRP mg/dL 0.54 (0.4; 17.3) 1.15 (0.4; 21.1)
WBC (K/μL) 8.2 (4.0; 29.9) 7.5 (3.6; 26.4)
Montreal age (yr) A1 < 16 0 (0) 4 (3)
A2 17-40 29 (51) 47 (36)
A3 > 40 28 (49) 80 (61)
Montreal class UC E1 proctitis 4 (7)
E2 distal 17 (30)
E3 extensive 36 (63)
Disease activity by DAI Mild (1) 11 (19)
Moderate (2) 27 (48)
Severe (3) 19 (33)
Montreal class CD L1 ileal 45 (34)
L2 colonic 57 (44)
L3 ileocolonic 29 (22)
L4 isolated upper 0 (0)
B1 nonstricturing 95 (73)
B2 stricturing 24 (18)
B3 penetrating 12 (9)
P perianal 4 (3)
Disease activity by SES-CD Inactive (0-2) 9 (10)
Mild (3-6) 20 (22)
Moderate (7-15) 26 (28)
Severe (≥ 16) 37 (40)
WBC was significantly different only between patients with colonic and those with
combined colonic  and small  bowel  disease  (Figure  3C).  In  patients  with  colonic
disease, FL levels were associated with the number of inflamed colon segments (Table
4). Patients with 0-1 inflamed segments had a median FL level of 8 µg/g. Patients with
6 to 7 inflamed segments had a median level of 789 µg/g. Overall the association was
highly significant (Kruskal Wallis test: P < 0.001).
DISCUSSION
Colonoscopy is currently considered the standard test to diagnose and monitor IBD.
However, this procedure is invasive, costly and requires sedation and an inconvenient
preparation. Over the last two decades, fecal biomarkers such as FL and FC have
emerged as potential substitutes of endoscopy. The advantages of fecal biomarkers
are that samples (feces) are easy to obtain, can be collected at home, can be serially
obtained, and are relatively easy to analyze. This allows patients to regularly monitor
their disease without the need to see the clinician, by simply taking the stool sample
to  the  laboratory.  Hence,  fecal  biomarkers  in  principle  offer  a  convenient,  non-
invasive and low-cost option for disease monitoring. How to best use these indicators
to manage the disease is currently a subject of study and the initial results for FC are
encouraging[25]. Less studies are available for FL. Gisbert et al[17] measured FL and FC
in their  study cohort.  For FL they found that  elevated values correlated with an
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Figure 1
Figure 1  Biomarker levels according to disease severity measured by Simple Endoscopic Score for Crohn’s disease in Crohn’s disease patients. Analysis
of variance was used on natural log-transformed values of fecal lactoferrin, white blood cell and C-reactive protein to determine whether median values significantly
varied according to Simple Endoscopic Score for Crohn’s disease scores. Fecal lactoferrin (A) and, less, C-reactive protein (B) showed correlation with Simple
Endoscopic Score for Crohn’s disease categories. WBC median values were similar across all categories (C). SES-CD: Simple Endoscopic Score for Crohn’s disease;
WBC: White blood cell; CRP: C-reactive protein.
increased risk of relapse (25% risk with a positive result vs 10% with a negative result,
P < 0.05), and predicted relapse with a sensitivity of 62% and a specificity of 65%.
Siponnen and colleagues reported a correlation of FL with SES-CD and with colonic
histology in CD colitis,  but not in small  bowel disease[26].  In a recent review and
metanalysis Dai et al[22] reported the results of 10 studies which used a prospective
design and enrolled patients with diagnosed IBD. Overall the analysis revealed high
discrimination for assessing UC and CD activity with FL concentration, with the
diagnostic performance of the FL assay being apparently superior in UC patients. The
authors concluded that FL is an inexpensive and useful screening marker with high
sensitivity and modest specificity for assessing IBD activity[22].
In this retrospective study we investigated the correlation between FL levels and
mucosal  inflammation  as  well  as  disease  location  and  extent,  as  assessed  by
endoscopy and histology in both UC and CD patients. For comparison we also tested
the potential correlation of disease activity and location/extent with CRP and WBC –
two blood  markers  also  known to  be  elevated  in  inflammatory  states.  We  only
included patients who underwent endoscopy within 30 d of markers measurement.
The patient population was representative of the entire spectrum of disease severity.
The results show a positive, significant correlation of FL and CRP with SES-CD and
DAI. Such correlation was not seen for WBC. When stratifying patients for levels of
disease activity FL was able to separate inactive vs mild, inactive vs moderate, mild vs
severe and moderate vs severe activity in CD. In UC patients, FL separated mild vs
moderate, and mild vs severe disease activity. Importantly, in patients with exclusive
colonic  involvement  FL  levels  increased  with  the  number  of  colonic  segments
involved. FL levels were also elevated in 69% of active small bowel-only CD patients
with median FL levels significantly lower compared to patients with colonic-only
disease and combined colonic and small bowel disease (26 µg/g vs 304 µg/g vs 197
µg/g respectively). This finding suggests that low FL levels might be associated with
small bowel disease activity but with minimal, if any, colonic disease activity. This
could be related to the different surface area of the two intestinal tracts - whereby a
small extent of disease activity is relatively more significant in the small bowel than in
the  colon.  However,  the  precise  explanation  for  this  finding  (as  well  as  the
establishment of a FL cut-off level for inflammation in the colon vs small bowel) must
await a dedicated prospective study. Nevertheless, we show here that FL is a mostly
reliable indicator of small bowel disease. This finding disagrees with that of Sipponen
et  al[26],  who did  not  find correlation  of  fecal  markers  with  small  bowel  disease.
However,  those  authors  only  used  colonoscopy  to  estimate  the  disease
presence/extent in the small  bowel whereas we also relied on imaging.  Another
potential confounding factor in determining the accuracy of fecal markers in small
bowel disease is the unclear contribution of inflammation in the deeper layers of the
gut wall[27]. Regardless, the finding that FL levels are correlated with the disease extent
is an important one because it does indicate that this marker might be an accurate
indicator of the total disease burden - the product of severity times extent[28] - and
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Figure 2
Figure 2  Biomarker levels according to disease severity measured by Disease Activity Index in ulcerative colitis patients. Analysis of variance was used on
natural log-transformed values of fecal lactoferrin, white blood cell and C-reactive protein to determine whether median values significantly varied according to Disease
Activity Index scores. Fecal lactoferrin (A) and C-reactive protein (B) showed correlation with Disease Activity Index categories. WBC median values were similar
across all categories (C). DAI: Disease Activity Index; WBC: White blood cell; CRP: C-reactive protein.
makes it a potential candidate as an ideal therapeutic target, as already indirectly
shown by others for FC[25].
Another  interesting  finding  of  our  study  is  that  FL  levels  obtained  before
colonoscopy had a better correlation with SES-CD and DAI than levels measured after
the colonoscopy in patients given effective, fast acting medications (steroids and
biologics)  in  between marker  determination and the procedure.  The most  likely
explanation of this observation is that FL is a timely indicator of changes in disease
activity  after  therapy.  FL  concentration  in  feces  is  proportional  to  neutrophil
translocation to the mucosa of the GI tract – a process that is quickly modulated by the
activity of the inflammatory process[19]. Replacement of the dead epithelial cells on the
other hand might be more lengthy[29]. In principle, such timeliness of FL reaction to
changes in the mucosa inflammatory activity in IBD could be exploited to monitor
treatment response in a number of clinical scenarios.
Our  study  has  some  obvious  limitations.  Firstly,  it  is  a  retrospective  study.
However,  the data were retrieved from a single EMR and included detailed and
uniform information on patients’  clinical  status,  disease  features  and treatment.
Although FL was not tested for research purposes the timing and accuracy of data
acquisition would not have been different in a prospective study. Secondly, our study
is a single center study. As such it is possible that it might reflect the investigators’
and the institution standard of practice as they relate to several aspects of this study.
However, we applied the strictest and most objective criteria to select our patients’
population – according to widely used standards. Furthermore, the size of our patient
population and the representation of the spectrum of disease activity and extent are
well above the average of studies focused on FL[22].
Further validation of our findings in larger scale and prospective studies might
confirm that fecal markers of inflammation are accurate and inexpensive indicators of
disease activity in IBD, can be used in a number of clinical scenarios and should
become part of the standard armamentarium of the practicing gastroenterologist,
especially in the United States where their use still lags behind most other Western
countries[30].
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Table 2  Correlation of Simple Endoscopic Score for Crohn’s disease and Disease Activity Index and biomarkers








bP < 0.01. DAI: Disease Activity Index; SES-CD: Simple Endoscopic Score for Crohn’s disease; WBC: White blood cell; CRP: C-reactive protein; FL: Fecal
lactoferrin.
Table 3  Spearman correlation of fecal lactoferrin with Simple Endoscopic Score for Crohn’s disease and Disease Activity Index
according to timing of tests
Endoscopic scores Analysis FL pre colonoscopy FL post colonoscopy
SES-CD Correlation Coefficient 0.596b 0.285
N 58 27
DAI Correlation Coefficient 0.402a 0.054
N 38 16
aP < 0.05,
bP < 0.01. DAI: Disease Activity Index; SES-CD: Simple Endoscopic Score for Crohn’s disease; FL: Fecal lactoferrin.
Table 4  Median fecal lactoferrin vs extent of colonic disease





Kruskal Wallis test P < 0.001. FL: Fecal lactoferrin.
Figure 3
Figure 3  Biomarker levels according to disease location. Analysis of variance was used on natural log-transformed values of fecal lactoferrin, white blood cell and
C-reactive protein to determine whether median values significantly varied according to disease location. Fecal lactoferrin levels (A) were significantly higher in
patients with colonic and combined colonic and small bowel disease compared to patients with small bowel disease only. C-reactive protein (B) showed a similar trend
while white blood cell (C) was significantly different only between patients with colonic and those with combined colonic and small bowel disease. WBC: White blood
cell; CRP: C-reactive protein; SB: Small bowel.
WJGP https://www.wjgnet.com December 31, 2019 Volume 10 Issue 5




Studies have demonstrated a potential role for fecal biomarkers such as fecal calprotectin (FC)
and fecal lactoferrin (FL) in monitoring inflammatory bowel diseases (IBD) – both Crohn’s
disease (CD) and ulcerative colitis (UC). However, their correlation to endoscopic scores, disease
severity and affected intestinal surface has not been extensively investigated.
Research motivation
Achieving a better understanding of the role of fecal markers for the evaluation and mana-
gement of IBD patients.
Research objectives
To correlate FL, and for comparison white blood cell (WBC) and C-reactive protein (CRP), with
endoscopic scores, disease extent and location in CD and UC.
Research methods
Retrospective analysis in 188 patients who had FL, WBC and CRP determined within 30 d of
endoscopy. Disease location, disease extent (number of intestinal segments involved), disease
severity [determined by endoscopic scores: Simple Endoscopic Score for CD (SES-CD) and the
endoscopic component of the Mayo Clinical score/Disease Activity Index (DAI)], timing of FL
testing in relation to colonoscopy, as well as the use of effective fast acting medications (steroids
and biologics) between colonoscopy and FL measurement, were recorded.
Research results
In 131 CD and 57 UC patients, both CRP and FL - but not WBC - distinguished disease severity
(inactive,  mild,  moderate,  severe).  In  patients  receiving  fast-acting  treatment  (steroids  or
biologics) in between FL measurement and colonoscopy, FL showed a higher correlation to
endoscopic scores when tested before vs after the procedure (r = 0.596, P < 0.001 vs r = 0.285, P =
0.15,  for  SES-CD;  and  r  =  0.402,  P  =  0.01,  vs  r  =  0.054,  P  =  0.84  for  DAI).  Finally,  FL  was
significantly correlated with the diseased mucosal surface (colon-ileocolon > small bowel) and
the number of inflamed colon segments. FL and CRP separated disease severity categories. FL
showed a close correlation with the involved mucosal surface and with disease extent and was
more closely correlated to endoscopy when determined before the procedure – this indicating
that inflammatory activity changes associated with therapy might be rapidly reflected by FL
levels.
Research conclusions
The results show a positive, significant correlation of FL and CRP with SES-CD and DAI. FL
showed a close correlation with the diseased mucosal surface and with disease extent and was
more closely correlated to endoscopy when determined before endoscopy. FL can accurately and
timely represent intestinal inflammation in IBD.
Research perspectives
Further validation of our findings in large scale and prospective studies might confirm that fecal
markers of inflammation are accurate and inexpensive indicators of disease activity in IBD, can
be  used  in  a  number  of  clinical  scenarios  and  should  become  part  of  the  standard
armamentarium of the practicing gastroenterologist.
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